In a recent statement, Mojisola Adeyeye, the Director-General of the National Food and Drug Administration and Control (NAFDAC), announced that the Federal Government has granted approval to 105 drug manufacturing facilities.
NAFDAC received a total of 143 applications and carefully selected the approved companies based on stringent criteria. Adeyeye emphasized the importance for these companies to adhere to the Good Manufacturing Practices (GMP) guidelines set by the World Health Organization (WHO) and the NAFDAC GMP for Medicinal Products Regulations 2021.
This approval comes at a time when global pharmaceutical giants like GlaxoSmithKline (GSK) and Sanofi have exited the Nigerian market. It presents an opportunity for domestic drug manufacturers to fill the gap and contribute to the country’s healthcare sector.
The government’s decision to approve these drug manufacturing firms reflects its commitment to promoting local production and ensuring the availability of high-quality medications within Nigeria. It is a significant step towards achieving self-sufficiency in the pharmaceutical industry and reducing dependence on imports.
The approved companies are now expected to operate in accordance with international standards and regulations, maintaining strict quality control measures to ensure the safety and efficacy of their products. This move not only benefits the local economy but also enhances access to affordable and reliable medicines for the Nigerian population.
By encouraging the growth and development of the domestic pharmaceutical sector, the government aims to create employment opportunities, retain investments, and foster innovation in healthcare.